OR WAIT null SECS
© 2022 MJH Life Sciences and BioPharm International. All rights reserved.
© 2022 MJH Life Sciences™ and BioPharm International. All rights reserved.
June 13, 2022
Precision BioSciences has released clinical trial data on CAR T therapy candidates PBCAR0191, PBCAR19B, and PBCAR269A.
May 16, 2022
To build trust and ensure a high-quality product, companies must be sure their contracts are firm and their lines of communication even firmer.
March 09, 2022
New technologies are treatments are emerging to tackle COVID-19 and its assortment of new variants.
January 02, 2022
Although mRNA and viral vector vaccines have been top of mind for COVID-19 treatments, other technologies and treatments are emerging—along with new variants.
December 09, 2021
Sanofi’s acquisition of Origimm Biotechnology will add to its pipeline of vaccine candidates for treating acne.
November 19, 2021
Secarna Pharmaceuticals and Achilles Therapeutics have entered into an agreement to optimize the development of T cell therapies in Achilles’ pipeline.
November 01, 2021
The biopharma industry is seeing more merit in strategizing clinical and commercial drug development as early as the preclinical phase.
October 11, 2021
MilliporeSigma, the U.S. and Canadian Life Science business of Merck KGaA, Darmstadt, Germany, signed an agreement with Cellecta to license its genome-editing tool.
September 30, 2021
In September, Codex DNA released a full-length synthetic genome for the SARS-CoV-2 delta variant, which may accelerate discovery and development of diagnostics and treatments for COVID-19.
September 29, 2021
GeneTx Biotherapeutics and Ultragenyx Pharmaceutical announced that FDA has removed the clinical hold on GTX-102, an investigational treatment for Angelman syndrome.